FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling BPC 157 Erectile Dysfunction: What the Evidence Shows and Practical Considerations Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA Warning Letter to Great Lakes College of BioethicsWatch The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York